Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Accumulated Expenses (2024 - 2025)

Historic Other Accumulated Expenses for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $6.3 million.

  • Kura Oncology's Other Accumulated Expenses rose 15421.39% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 15421.39%. This contributed to the annual value of $2.7 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Kura Oncology reported Other Accumulated Expenses of $6.3 million as of Q3 2025, which was up 15421.39% from $4.5 million recorded in Q2 2025.
  • Kura Oncology's 5-year Other Accumulated Expenses high stood at $6.3 million for Q3 2025, and its period low was $1.8 million during Q2 2024.